NASDAQ:RVPH Reviva Pharmaceuticals Q4 2024 Earnings Results & Report $0.34 +0.05 (+17.96%) As of 11/20/2026 03:57 PM Eastern Reviva Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$3.00 versus the -$4.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 31, 2025TimeAfter Market ClosesConference Call8:00 AM ET Reviva Pharmaceuticals EPS ResultsActual EPS-$3.00Consensus EPS -$4.40Beat/MissBeat by +$1.40One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersReviva Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Reviva Pharmaceuticals Q4 2024 Earnings FAQ Did Reviva Pharmaceuticals beat earnings estimates for Q4 2024? Reviva Pharmaceuticals (NASDAQ:RVPH) reported earnings of -$3.00 per share for Q4 2024, beating the consensus estimate of -$4.40. The report was announced on Monday, March 31, 2025. Reviva Pharmaceuticals Earnings HeadlinesRVPH: FDA Feedback on New Formulation ImminentNovember 17, 2026 | msn.comReviva Pharmaceuticals Reports FDA Feedback Timeline, New Brilaroxazine Patent Progress and Q3 2026 ResultsNovember 12, 2026 | quiverquant.comQWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 22 at 1:00 AM | Porter & Company (Ad)Reviva Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 12, 2026 | globenewswire.comReviva Pharmaceuticals op Lytham Partners: brilaroxazine vordertSeptember 29, 2026 | nl.investing.comReviva Pharmaceuticals alla conferenza Lytham Partners: avanza brilaroxazineSeptember 29, 2026 | it.investing.comSee More Reviva Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email. Email Address About Reviva PharmaceuticalsReviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing treatments for disorders involving the central nervous system, respiratory system and inflammation. The company is headquartered in Cupertino, California, and was founded in 2006. Its lead drug candidate, brilaroxazine (also known as RP5063), is an investigational compound being developed for schizophrenia and other neuropsychiatric conditions. Reviva has also described potential applications for the candidate in respiratory and other disorders. Brilaroxazine is not an approved or marketed medicine. Reviva’s work centers on research and clinical development of its drug candidates; the company does not currently offer commercial pharmaceutical products.View Reviva Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.